Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 496 entries
View as:

A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia

Phase: N/A Priority: Normal
NCT ID: NCT04372186 Org: User:
Start: 05/14/20 End: 09/22/20 Due: 09/22/21

A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation

Phase: N/A Priority: Normal
NCT ID: NCT02136524 Org: User:
Start: 04/30/14 End: 05/31/14 Due: 05/31/15

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01226277 Org: User:
Start: 10/31/10 End: 09/30/12 Due: 09/30/13

A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02063581 Org: User:
Start: 02/28/14 End: 03/31/14 Due: 03/31/15

A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

Phase: N/A Priority: Normal
NCT ID: NCT00694980 Org: User:
Start: 09/30/08 End: 09/30/12 Due: 09/30/13

Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential

Phase: N/A Priority: Normal
NCT ID: NCT02621957 Org: User:
Start: 12/31/15 End: 02/29/16 Due: 02/28/17

A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00664898 Org: User:
Start: 05/31/08 End: 04/08/10 Due: 04/08/11

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01442090 Org: User:
Start: 10/31/11 End: 07/31/15 Due: 07/31/16

An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)

Phase: N/A Priority: Normal
NCT ID: NCT00097240 Org: User:
Start: 01/31/05 End: 09/30/09 Due: 09/30/10

A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)

Phase: N/A Priority: Normal
NCT ID: NCT00312728 Org: User:
Start: 03/31/06 End: 06/30/09 Due: 06/30/10

A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease

Phase: N/A Priority: Normal
NCT ID: NCT02353598 Org: User:
Start: 02/26/15 End: 03/26/19 Due: 03/26/20

A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma

Phase: N/A Priority: Normal
NCT ID: NCT00495612 Org: User:
Start: 09/30/07 End: 06/30/09 Due: 06/30/10

A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01432353 Org: User:
Start: 09/30/11 End: 04/30/14 Due: 04/30/15

An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)

Phase: N/A Priority: Normal
NCT ID: NCT00726661 Org: User:
Start: 06/30/08 End: 12/31/12 Due: 12/31/13

An Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)

Phase: N/A Priority: Normal
NCT ID: NCT00669045 Org: User:
Start: 09/01/00 End: 03/31/06 Due: 03/31/07

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette)

Phase: N/A Priority: Normal
NCT ID: NCT05626114 Org: User:
Start: 03/23/23 End: 03/01/31 Due: 03/01/32

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06031441 Org: User:
Start: 11/27/23 End: 12/31/26 Due: 12/31/27

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Phase: N/A Priority: Normal
NCT ID: NCT06096779 Org: User:
Start: 07/15/24 End: 11/16/26 Due: 11/16/27

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Phase: N/A Priority: Normal
NCT ID: NCT00090623 Org: User:
Start: 08/31/04 End: 03/31/07 Due: 03/31/08

A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study

Phase: N/A Priority: Normal
NCT ID: NCT00096941 Org: User:
Start: 05/31/05 End: 10/31/07 Due: 10/31/08

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00080223 Org: User:
Start: 08/31/03 End: 04/30/15 Due: 04/30/16

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01485861 Org: User:
Start: 01/11/12 End: 08/31/22 Due: 08/31/23

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05581004 Org: User:
Start: 10/20/22 End: 02/28/27 Due: 02/28/28

National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin

Phase: N/A Priority: Normal
NCT ID: NCT00097539 Org: User:
Start: 10/31/85 End: 06/30/10 Due: 06/30/11

A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02146313 Org: User:
Start: 06/22/14 End: 06/18/18 Due: 06/18/19